Innovent Biologics

The New Drug Application for picankibart injection, a recombinant anti-IL-23p19 antibody, has been accepted by the Center for Drug Evaluation of China's NMPA for the treatment of moderate to severe plaque psoriasis. As the first IL-23p19 antibody to demonstrate over 80% of subjects achieving PASI 90 at 16 weeks, picankibart also offers the longest maintenance dosing interval in its class, delivering significant clinical benefits and improving quality of life for patients. https://lnkd.in/gCjgDQ9N #InnoventBiologics #psoriasis

Congratulations to the recipients of the 2024 #LaskerAward for their groundbreaking work in GLP-1-based drugs, transforming obesity treatment worldwide. Their discoveries laid the foundation for a new generation of therapies, including the GLP-1R/GCGR dual agonist Mazdutide, which builds on the successes of earlier treatments, expanding the potential for even greater weight loss and metabolic health improvements. Learn more about the remarkable history and future of GLP-1-based therapies below. The Albert and Mary Lasker Foundation #InnoventBiologics #Mazdutide #glp1 https://lnkd.in/eG3SyZAN https://lnkd.in/g4_8cpmc

At #ESMO24, we also had the valuable opportunity to present clinical data for IBI354, a HER2 monoclonal antibody-camptothecin derivative conjugate. With extremely low exposure of free toxin in circulation and an ideal safety profile from pre-clinical and clinical studies, IBI354 shows great promise for patients with advanced tumor types, including breast cancer, ovarian cancer and colorectal cancer. https://lnkd.in/g2D2Qwgk

Exciting new clinical data on IBI363, Innovent's first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, in combination with bevacizumab for advanced colorectal cancer has been shared at the 2024 ESMO - European Society for Medical Oncology . With ongoing studies investigating IBI363 in other cancers such as NSCLC, melanoma, and additional solid tumors, we remain hopeful about its potential to bring new treatment options to even more patients. https://lnkd.in/gJHjwqAd #ESMO24 #InnoventBiologics #OncologyCommunity

Our Phase 3 DREAMS-2 trial results for mazdutide, a GLP-1R and GCGR dual agonist, were presented as a late-breaking session at #EASD2024. Mazdutide showed superior glycemic control and weight reduction compared to dulaglutide in Chinese adults with type 2 diabetes, along with improvements in key cardiometabolic risk factors. Access the EASD presentation results below. https://lnkd.in/gZheqzBQ 

We're excited to share encouraging Phase 1 clinical data for IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, at the 2024 World Conference on Lung Cancer. The data shows efficacy in advanced NSCLC, offering new treatment possibilities for patients with limited options. With ongoing Phase 1/2 trials, we remain committed to advancing innovative therapies for those in need. https://lnkd.in/gY2aWHKj #InnoventBiologics #wclc24

Innovent Biologics, in partnership with Stars Youth Development Center, has successfully completed its third annual Children's Book Donation event, distributing nearly 2,000 books to three rural primary schools in Shanxi, Gansu, and Inner Mongolia, and benefiting nearly 2,000 students and teachers. This initiative seeks to close the educational resource gap in remote areas by providing carefully selected literature to inspire creativity and broaden horizons for children. This book donation is part of Innovent's broader commitment to community well-being, which also includes running free clinics, organizing employee blood drives, holding appreciation events for caregivers, and managing extensive patient assistance programs. With drug donations worth over RMB 3.4 billion reaching more than 170,000 patients, these initiatives, fueled by the dedication of our teams, truly bring our mission to life: developing high-quality, affordable biopharmaceuticals while making a meaningful difference in the communities we serve.

We're excited to connect with the oncology community at the 2024 World Conference on Lung Cancer in San Diego, where our team will present updated results from the pivotal Phase 2 trial of Dupert® (fulzerasib) for advanced NSCLC with the KRAS G12C mutation. As a potent KRAS G12C inhibitor, Dupert® represents an innovative treatment option for patients who have received prior systemic therapy, recently earning NMPA approval. https://lnkd.in/g6FbhrX9 #InnoventBiologics #wclc24

Roundhill Investments has launched OZEM, an actively managed ETF centered on the expanding weight loss drug market. This ETF features #InnoventBiologics as one of its holdings, representing 5% of the portfolio. This strategic inclusion reflects a balanced approach to capturing growth from both established leaders and innovative entrants in the sector. We're proud of our team's hard work and stand behind mazdutide's success in clinical trials. With Goldman Sachs projecting that the obesity treatment market could reach $100 billion by 2030, OZEM aims to leverage a broad spectrum of opportunities within this growing field. To gain deeper insights into this new ETF, watch the full interview here: https://lnkd.in/gMptMerH #Mazdutide #WeightLoss

Exciting news! Innovent's PD-1/IL-2α bispecific antibody fusion protein (IBI363) has earned FDA Fast Track Designation, marking a significant step forward in the fight against unresectable advanced or metastatic melanoma for patients who have progressed after PD-1/L1 inhibitor therapy. Ongoing trials in China, the U.S. and Australia are actively assessing the efficacy and safety of IBI363 in tackling advanced malignant tumors. https://lnkd.in/gp7Sf49x #InnoventBiologics #Oncology